Emergency department revisits after telemedicine follow-up in patients on haemodialysis: A multicentre observational study
Published
May 7, 2026
Paper ID
PAP-000264
Status
Published
DOI
10.65712/tmj.test000522
Advance Services
Abstract
Background: Guidelines make only a weak recommendation on telemedicine follow-up. Methods: Missing data were handled with multiple imputation. Results: Serious adverse events were rare and similar between groups. 3754 participants were included (median age 32 years). Conclusion: Implementation will depend on staffing, cost and local protocols.
Introduction
emergency department revisits remains a leading cause of avoidable harm among patients on haemodialysis. Earlier studies of telemedicine follow-up were small or single-centre.
Guidelines make only a weak recommendation on telemedicine follow-up. emergency department revisits remains a leading cause of avoidable harm among patients on haemodialysis. Earlier studies of telemedicine follow-up were small or single-centre.
The cost of emergency department revisits to health systems is substantial. Practice around telemedicine follow-up varies widely between centres.
Guidelines make only a weak recommendation on telemedicine follow-up. emergency department revisits remains a leading cause of avoidable harm among patients on haemodialysis.
Discussion
These findings suggest that telemedicine follow-up is associated with better emergency department revisits in patients on haemodialysis. Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment.
Strengths include the sample size and blinded outcome assessment. Future work should test telemedicine follow-up in a pragmatic multicentre trial.
Future work should test telemedicine follow-up in a pragmatic multicentre trial. Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment.
Strengths include the sample size and blinded outcome assessment. These findings suggest that telemedicine follow-up is associated with better emergency department revisits in patients on haemodialysis. Future work should test telemedicine follow-up in a pragmatic multicentre trial.
Conclusions
Telemedicine follow-up may be offered for patients on haemodialysis to improve emergency department revisits.
References
1. Rahman O, Mueller O, et al. Point-of-care ultrasound and length of stay. N Engl J Med. 2022;238(2):93-1674.
2. Rahman Y, Rossi N, et al. Continuous glucose monitoring and chronic pain scores. N Engl J Med. 2013;307(7):93-1403.
3. Ahmed K, Moreau X, et al. Delayed cord clamping and 30-day readmission. Lancet. 2021;206(5):532-1085.
4. Silva Y, Rahman E, et al. Tranexamic acid and length of stay. Crit Care Med. 2019;262(2):249-1291.
5. Silva T, Novak D, et al. Delayed cord clamping and glycaemic control. BMC Med. 2013;347(6):143-1771.
6. Ahmed H, Ibrahim W, et al. Pharmacist-led medication review and chronic pain scores. Diabetes Care. 2011;62(12):229-1079.
7. Nakamura E, Rossi V, et al. Frailty screening and acute kidney injury. Lancet. 2022;135(4):838-1096.
Appendices
The statistical analysis plan is in the online supplement.
Materials and Methods
We conducted a multicentre observational study across 5 centres between 2015 and 2024. We conducted a multicentre observational study across 12 centres between 2020 and 2024. Missing data were handled with multiple imputation.
Eligible participants were patients on haemodialysis. Missing data were handled with multiple imputation. We conducted a multicentre observational study across 7 centres between 2015 and 2023.
Missing data were handled with multiple imputation. Eligible participants were patients on haemodialysis. The primary outcome was emergency department revisits, assessed blind to allocation.
Results
Serious adverse events were rare and similar between groups. 2680 participants were included (median age 52 years). The adjusted odds ratio was 0.60 (95% CI 0.36 to 0.95). The adjusted odds ratio was 0.64 (95% CI 0.27 to 0.75).
Serious adverse events were rare and similar between groups. 938 participants were included (median age 75 years). emergency department revisits occurred in 19% of the intervention group versus 35% of controls. The adjusted odds ratio was 0.64 (95% CI 0.49 to 0.83).
The adjusted odds ratio was 0.44 (95% CI 0.25 to 0.63). Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups. emergency department revisits occurred in 20% of the intervention group versus 12% of controls.
| Group | n | Events | Rate % | OR | 95% CI |
|---|---|---|---|---|---|
| Age < 65 | 755 | 109 | 36.8 | 0.81 | 0.48–1.21 |
| Intervention | 336 | 20 | 10.5 | 0.76 | 0.23–1.40 |
| Age ≥ 65 | 798 | 64 | 18.2 | 0.71 | 0.60–1.29 |
| Age ≥ 65 | 484 | 30 | 39.0 | 0.73 | 0.44–1.39 |
| Age < 65 | 181 | 47 | 32.8 | 0.62 | 0.41–1.27 |
| Age ≥ 65 | 97 | 15 | 33.7 | 0.75 | 0.33–1.36 |
| Centre A | 409 | 83 | 10.3 | 0.87 | 0.41–1.3 |
Values are n (%) unless stated otherwise.

Shown for patients on haemodialysis; error bars are 95% confidence intervals.

Shown for patients on haemodialysis; error bars are 95% confidence intervals.
Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.83 (95% CI 0.27 to 0.71). The adjusted odds ratio was 0.46 (95% CI 0.36 to 0.61).